AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Poxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019

March 11, 2019

LYON, France--(BUSINESS WIRE)--Mar 11, 2019--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that it will report its financial results for the full year 2018 on Thursday, March 21, 2019.

The management team will host a conference call on March 21, 2019 in English at 2:30 pm EDT (New York time) / 7:30 pm CET (Paris time) to discuss the financial results and provide a corporate update.

To access the conference call, please use one of the following dial-in numbers and connect at least 5 minutes prior to the scheduled start time:
US: +1 646-722-4916
UK: +44 (0) 207 194 3759
FR: +33 (0)1 72 72 74 03
Followed by the PIN code: 89356541#

A slide presentation will be available in the “Investors / Shareholder Information/ Regulatory Documentation 2018” section of the Poxel website shortly before the conference call.

Following the live call, a replay will be available for 90 days. To access the replay, please use one of the following numbers:
US: +1 646-722-4969
UK: +44 20 3364 5147
FR: +33 (0)1 70 71 01 60
Followed by the PIN code: 418836924#

About Poxel SA
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL,  www.poxelpharma.com )

View source version on businesswire.com:https://www.businesswire.com/news/home/20190311005512/en/

CONTACT: Poxel SA

Jonae R. Barnes

Senior Vice President, Investor Relations and Public Relations

jonae.barnes@poxelpharma.com

+1 617 818 2985

Investor relations / Media - EU/US

Trophic Communications

Gretchen Schweitzer or Stephanie May

may@trophic.eu

+49 89 238 877 34 or +49 171 185 56 82

Investor relations / Media - France

NewCap

Alexia Faure/Nicolas Merigeau

poxel@newcap.eu

+33 1 44 71 94 94

KEYWORD: UNITED STATES EUROPE NORTH AMERICA FRANCE MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL DIABETES

SOURCE: Poxel SA

Copyright Business Wire 2019.

PUB: 03/11/2019 12:45 PM/DISC: 03/11/2019 12:45 PM

http://www.businesswire.com/news/home/20190311005512/en